2025-04-02
The Optimal Timing for Initiating Anamorelin in the Treatment of Cancer Cachexia
2025-04-02 • Mami Ogura, Hiroshi Matsuoka, S Shinohara, Yusuke Umeki, Noriaki Mastumoto, Tomohiro Mizuno, Masanobu Usui, Yoshiki Hirooka, Kazuyoshi Imaizumi, Ko...
Objective In 2021, anamorelin, an orally active ghrelin receptor selective antagonist, was approved for the treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colon cancer. Cancer cachexia is classified into three stages: pre-cachexia, cachexia, and refractory cachexia, with the pre-cachexia and cachexia stages considered reversible with a combination of nutritional therapy, pharmacotherapy, and exercise therapy. In addition, treatment of cachexia requires ear…